Dr. Asnat Raziel

My articles

My articles

Wegovy for overweight and mild obesity: 15.1% weight loss in a year in the SHIFT study

Wegovy for overweight: what the new study found

Wegovy for overweight and mild obesity led to an average weight loss of 15.1% after one year. That is the main finding of the SHIFT study, presented at the ObesityWeek meeting in Washington. In addition, one in five patients reached a normal weight. It is one of the first studies to look at treatment in this group specifically.

I see many people like this in my clinic. Their weight is not “extreme,” but it already affects their health, their mobility and how they feel. So they rightly ask: is this medication for me too?

Why mild obesity deserves its own study

Most large Wegovy trials enrolled people with an average BMI of 35 or more. BMI, or body mass index, is weight in kilograms divided by height in meters squared. People with overweight (BMI 25 to 29.9) or class I obesity (BMI 30 to 34.9) are at an earlier stage of the disease. They usually have fewer complications, so there was less data on how they do.

Yet this is exactly the stage where prevention is possible. Losing weight before diabetes, heart disease or joint problems appear can change the course of things.

The SHIFT study: who took part

SHIFT is a retrospective study, meaning it analyzed data that had already been collected. The researchers used US medical records and insurance claims. They looked at adults who started semaglutide injections, the active ingredient in Wegovy, for weight management between June 2021 and March 2025.

All participants had overweight with at least one weight-related condition, or class I obesity. None had diabetes. The researchers included only people who stayed on treatment for a full year, with no gap of more than 60 days. The lead investigator is Dr. Domenica Rubino, an obesity medicine specialist from Washington.

Who the patients were

The study included 6,698 patients. Mean age was 50, and 76% were women. Mean starting weight was 90 kg, and mean BMI was 31.9. In other words, 87% had class I obesity and 13% had overweight.

Despite their relatively “mild” weight, many patients had health problems. For example, 54% had high blood fats, 47% had muscle and joint pain, and 40% had high blood pressure. In addition, 36% had anxiety and 27% had prediabetes.

Wegovy for overweight: weight results

Among 2,171 patients weighed both at the start and after one year, weight fell by an average of 15.1%. That is 13.5 kg, from a mean of 90.0 kg down to 76.5 kg. For example, a woman who started at 85 kg dropped to about 72 kg on average.

For comparison, in the STEP 1 trial, Wegovy’s large controlled trial, average weight loss was 14.9% after 68 weeks. So the result here is impressive. Still, we can’t compare the two directly, because SHIFT included only people who stayed on treatment.

Moving down a BMI class

Among 4,810 patients with BMI measured at both time points, BMI fell by an average of 4.1 units. In addition, 64.5% moved to a lower BMI class. The share of patients with obesity fell from 87.0% to 29.4%.

The most striking figure is normal weight. After one year, 20.4% of patients reached a BMI under 25. Among those who started with overweight, 50.1% reached a normal weight. Among those who started with class I obesity, 15.9% did.

Wegovy for overweight: infographic of SHIFT study results

Wegovy for overweight: heart, blood sugar and blood fats

Beyond weight, health markers also improved, and every change was statistically significant. Systolic blood pressure, the top number, fell by 6.0 mm Hg. Diastolic blood pressure, the bottom number, fell by 3.0 mm Hg. In addition, HbA1c, the three-month blood sugar average, fell by 0.3 percentage points.

Blood fats improved too. LDL, the “bad” cholesterol, fell by about 12.4%. Triglycerides fell by about 23.3%, and HDL, the “good” cholesterol, rose by about 2.4%. In other words, weight loss came with better heart-risk markers.

What the study does not tell us

These data need careful reading. First, this is an observational study without a comparison group. It shows a link between treatment and outcomes, but it does not prove the drug was the only cause. Second, the study included only people who stayed on treatment for a full year. It left out those who stopped, for example because of side effects or cost.

In addition, not every patient had every measurement, and the study did not report side effects. Novo Nordisk, the maker of Wegovy, funded the study. Finally, the data come from the United States, where the health system differs from Israel’s.

What this means for you

These findings match what I see in my clinic: even with mild obesity, medication can make a meaningful difference. However, Wegovy is approved for weight management only from a BMI of 30, or from a BMI of 27 with a weight-related condition. So not everyone with overweight is a candidate.

Before starting, it is worth knowing Wegovy’s side effects. In addition, combine treatment with a protein-rich diet and strength training to protect your muscle. The results in this study came from people who stayed on treatment, so sticking with it is part of the key.

The bottom line on Wegovy for overweight

In the SHIFT study, Wegovy for overweight and class I obesity led to 15.1% weight loss in a year. About one in five patients reached a normal weight, and blood pressure, blood sugar and blood fats improved. However, this is an observational study of people who stayed on treatment. You and your doctor should choose the right treatment together. A summary of everything Novo presented at the meeting is in my article on Novo at ObesityWeek.

This article is general information and does not replace personal medical advice.

References

Real-World Clinical Outcomes with Semaglutide in a Population with Overweight or Class I Obesity

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Obesity Week 2026 – Novo Nordisk Science Hub

The study was funded by Novo Nordisk.

Wegovy for overweight: a young man playing table tennis in a bright sports hall

Dr. Asnat Raziel